Details of Disease

General Information of Disease (ID: DISLIZS4)

• Disease Name: Hyperprolactinaemia
• Synonyms: inappropriate prolactin secretion syndrome; syndrome, prolactin hypersecretion; hyperprolactinemias; secretion prolactin, inappropriate; prolactin secretion, inappropriate; inappropriate prolactin secretion; prolactin, inappropriate secretion; inappropriate secretion prolactin; secretion, inappropriate prolactin; prolactin hypersecretion syndrome; hypersecretion syndrome, prolactin; hyperprolactinemia (disease); hyperprolactinaemia; hyperprolactinemia
• Disease Class: 5A60-5A61: Pituitary gland disorder
• Definition: Abnormally high level of prolactin in the blood.
• Disease Hierarchy:
  DISCNV73: Hyperpituitarism
  DISLIZS4: Hyperprolactinaemia
• ICD Code:
  ICD-11: ICD-11: 5A60.1
  ICD-10: ICD-10: E22.1
  ICD-9: ICD-9: 253.1
  Expand ICD-11: '5A60.1
  Expand ICD-10: 'E22.1
  Expand ICD-9: 253.1
• Disease Identifiers:
  MONDO ID: MONDO_0005804
  MESH ID: D006966
  UMLS CUI: C0020514
  OMIM ID: 615555
  MedGen ID: 5698
  SNOMED CT ID: 237662005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bromocriptine	DMVE3TK	Approved	Small molecular drug	[1]
Cabergoline	DMQ4HIN	Approved	Small molecular drug	[2]
Erenumab	DMWMCN0	Approved	NA	[3]
Fremanezumab	DMDZY54	Approved	Antibody	[3]
Galcanezumab	DMIZ1E8	Approved	Antibody	[3]
Metergolin	DMJFP6G	Approved	Small molecular drug	[4]
Quinagolide	DM7WI4Q	Approved	Small molecular drug	[5]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AMG 301	DMO72IF	Phase 2	NA	[6]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 12 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PRLR	TTBPXMA	Limited	Biomarker	[7]
GAD1	TTKGEP3	moderate	Biomarker	[8]
GNRH1	TT0ID4A	moderate	Biomarker	[9]
ABCC3	TTVLG21	Strong	Biomarker	[10]
CYP2D6	TTVG215	Strong	Biomarker	[11]
GH1	TTT3YKH	Strong	Biomarker	[12]
HTR2C	TTWJBZ5	Strong	Biomarker	[11]
HTR6	TTJS8PY	Strong	Biomarker	[13]
SLC6A3	TTVBI8W	Strong	Genetic Variation	[14]
SRD5A1	TTTU72V	Strong	Biomarker	[15]
SRD5A2	TTT02K8	Strong	Biomarker	[15]
TH	TTUHP71	Strong	Therapeutic	[16]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
HSD3B1	DERDQWN	Strong	Biomarker	[17]
HSD3B2	DEN0GVQ	Strong	Biomarker	[18]

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
LHB	OT5GBOVJ	moderate	Biomarker	[19]
SCARB2	OTN929M8	Strong	Genetic Variation	[20]

References

• [1] Bromocriptine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 37).
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [6] PACAP38 and PAC1 receptor blockade: a new target for headache J Headache Pain. 2018 Aug 7;19(1):64.
• [7] New insights into human prolactin pathophysiology: genomics and beyond.Curr Opin Obstet Gynecol. 2019 Aug;31(4):207-211. doi: 10.1097/GCO.0000000000000545.
• [8] [Modification of the nigro-striatal system by estrogens and prolactin. Clinical and experimental data].Boll Soc Ital Biol Sper. 1982 Aug 30;58(16):1054-60.
• [9] [The effect of luliberin and sulpiride on the secretion of gonadotropic hormones and prolactin in patients with obesity].Probl Endokrinol (Mosk). 1990 May-Jun;36(3):23-8.
• [10] Manifestation of multidrug resistance protein 3 (MRP3) in liver and kidney cells in cholestasis: effects of hyperprolactinemia.Bull Exp Biol Med. 2013 Feb;154(4):508-11. doi: 10.1007/s10517-013-1989-4.
• [11] Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):236-246. doi: 10.1111/bcpt.13323. Epub 2019 Oct 1.
• [12] Mixed gangliocytoma-pituitary adenoma in the sellar region: a large-scale single-center experience.Acta Neurochir (Wien). 2018 Oct;160(10):1989-1999. doi: 10.1007/s00701-018-3632-7. Epub 2018 Aug 14.
• [13] Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia.World J Biol Psychiatry. 2017 Apr;18(3):239-246. doi: 10.1080/15622975.2016.1224926. Epub 2016 Sep 22.
• [14] A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.BMC Med Genet. 2019 Apr 9;20(Suppl 1):47. doi: 10.1186/s12881-019-0773-3.
• [15] Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats.IUBMB Life. 2008 Jan;60(1):68-72. doi: 10.1002/iub.13.
• [16] Studies on the regulatory effect of Peony-Glycyrrhiza Decoction on prolactin hyperactivity and underlying mechanism in hyperprolactinemia rat model.Neurosci Lett. 2015 Oct 8;606:60-5. doi: 10.1016/j.neulet.2015.08.024. Epub 2015 Aug 18.
• [17] Effects of human chorionic gonadotropin (hCG) and prolactin (PRL) on 3 beta-hydroxy-5-ene-steroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) expression and activity in the rat ovary.Mol Cell Endocrinol. 1990 Aug 20;72(2):R7-13. doi: 10.1016/0303-7207(90)90107-j.
• [18] Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin.J Invest Dermatol. 1994 Jul;103(1):60-4. doi: 10.1111/1523-1747.ep12389663.
• [19] Pituitary sensitivity to LHRH in hyperprolactinemia induced by perphenazine and renal pituitary transplants in female rats.Biol Reprod. 1980 Apr;22(3):486-92. doi: 10.1095/biolreprod22.3.486.
• [20] Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects.J Child Adolesc Psychopharmacol. 2015 Dec;25(10):738-48. doi: 10.1089/cap.2015.0094.